Literature DB >> 8288948

The complement system and systemic sclerosis.

C Benbassat1, M Schlesinger, C Luderschmidt, G Valentini, G Tirri, Y Shoenfeld.   

Abstract

Serum concentrations of the various complement components including the classical and the alternative pathways were determined in 58 control healthy subjects and 80 patients with systemic sclerosis (SSC). The mean concentrations of C1q, C2, C5, C6, C7, C9, and factor B were significantly increased in the SSC patients in comparison to controls, while the increases were not significant for C3 and C8. C4 was an exception in that the mean levels were found to be decreased, with 18 patients having levels < 65% of the mean normal value. Properdin was also found to be decreased, but not significantly. We found a similarity between the pattern of serum complement component concentrations in SSC patients and patients with primary biliary cirrhosis, two disorders frequently associated in the same patients. The significance of complement component patterns in these diseases is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8288948     DOI: 10.1007/BF02918260

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  29 in total

Review 1.  Genetic factors in scleroderma.

Authors:  D Briggs; C Black; K Welsh
Journal:  Rheum Dis Clin North Am       Date:  1990-02       Impact factor: 2.670

2.  Activation of the complement system in systemic sclerosis. Relationship to clinical severity.

Authors:  G Senaldi; S Lupoli; D Vergani; C M Black
Journal:  Arthritis Rheum       Date:  1989-10

3.  Progressive systemic sclerosis: autoimmune arteriopathy.

Authors:  D J Evans; S J Cashman; M Walport
Journal:  Lancet       Date:  1987-02-28       Impact factor: 79.321

4.  Circulating immune complexes in patients with progressive systemic sclerosis.

Authors:  K Siminovitch; M Klein; W Pruzanski; S Wilkinson; P Lee; S J Yoon; E Keystone
Journal:  Arthritis Rheum       Date:  1982-10

5.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

6.  Systemic sclerosis (scleroderma): clinical, genetic, and serologic subsets.

Authors:  J Z Livingston; T E Scott; F M Wigley; G J Anhalt; W B Bias; R H McLean; M C Hochberg
Journal:  J Rheumatol       Date:  1987-06       Impact factor: 4.666

7.  The kidney in progressive systemic sclerosis: immunohistochemical and antibody elution studies.

Authors:  R C McCoy; C C Tisher; P F Pepe; L A Cleveland
Journal:  Lab Invest       Date:  1976-08       Impact factor: 5.662

8.  Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases.

Authors:  N Zurgil; R Bakimer; H M Moutsopoulos; A G Tzioufas; P Youinou; D A Isenberg; M Scheinberg; T Kveder; B Rozman; C Luderschmidt
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

9.  Complement profile in primary biliary cirrhosis.

Authors:  M Schlesinger; C Benbassat; Y Shoenfeld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

10.  Immune complexes in progressive systemic sclerosis (scleroderma).

Authors:  J R Seibold; T A Medsger; A Winkelstein; R H Kelly; G P Rodnan
Journal:  Arthritis Rheum       Date:  1982-10
View more
  8 in total

1.  European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes.

Authors:  G Valentini; A Della Rossa; S Bombardieri; W Bencivelli; A J Silman; S D'Angelo; M M Cerinic; J F Belch; C M Black; P Bruhlmann; L Czirják; A De Luca; A A Drosos; C Ferri; A Gabrielli; R Giacomelli; G Hayem; M Inanc; N J McHugh; H Nielsen; M Rosada; R Scorza; J Stork; A Sysa; F H van den Hoogen; P J Vlachoyiannopoulos
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Endothelial cells recruit macrophages and contribute to a fibrotic milieu in bleomycin lung injury.

Authors:  Heather G Leach; Izabela Chrobak; Rong Han; Maria Trojanowska
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

Review 3.  Innate Immunity in Systemic Sclerosis.

Authors:  Christopher Dowson; Nathan Simpson; Laura Duffy; Steven O'Reilly
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.592

4.  A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples.

Authors:  Diana Pauly; Benedikt M Nagel; Jörg Reinders; Tobias Killian; Matthias Wulf; Susanne Ackermann; Boris Ehrenstein; Peter F Zipfel; Christine Skerka; Bernhard H F Weber
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

5.  Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study.

Authors:  Michael Osthoff; Gene-Siew Ngian; Melinda M Dean; Mandana Nikpour; Wendy Stevens; Susanna Proudman; Damon P Eisen; Joanne Sahhar
Journal:  Arthritis Res Ther       Date:  2014-11-18       Impact factor: 5.156

6.  Role of C5 inhibition in Idiopathic Inflammatory Myopathies and Scleroderma Renal Crisis-Induced Thrombotic Microangiopathies.

Authors:  Anna Gouin; David Ribes; Magali Colombat; Dominique Chauveau; Gregoire Prevot; Olivier Lairez; Gregory Pugnet; Veronique Fremeaux-Bacchi; Antoine Huart; Julie Belliere; Stanislas Faguer
Journal:  Kidney Int Rep       Date:  2021-01-29

7.  Increased Complement Activation in Systemic Sclerosis Patients with Skin and Lung Fibrosis.

Authors:  Chiara Pellicano; Marzia Miglionico; Laura Romaggioli; Amalia Colalillo; Lorenzo Vantaggio; Cecilia Napodano; Cinzia Callà; Francesca Gulli; Mariapaola Marino; Umberto Basile; Edoardo Rosato
Journal:  J Pers Med       Date:  2022-02-15

8.  Network based systems biology approach to identify diseasome and comorbidity associations of Systemic Sclerosis with cancers.

Authors:  Md Khairul Islam; Md Habibur Rahman; Md Rakibul Islam; Md Zahidul Islam; Md Mainul Islam Mamun; A K M Azad; Mohammad Ali Moni
Journal:  Heliyon       Date:  2022-02-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.